DOCSLIB.ORG

Gastrointestinal Defense Mechanisms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gastrointestinal Defense Mechanisms REVIEW CURRENT OPINION Gastrointestinal defense mechanisms Hyder Said a,b and Jonathan D. Kaunitzb,c Purpose of review To summarize and illuminate the recent findings regarding gastroduodenal mucosal defense mechanisms and the specific biomolecules involved in regulating this process, such as glucagon-like peptides (GLPs). Recent findings There has been a growing interest in luminal nutrient chemosensing and its physiological effects throughout the digestive system. From the ingestion of food in the oral cavity to the processing and absorption of nutrients in the intestines, nutrient chemosensing receptors signal the production and release of numerous bioactive peptides from enteroendocrine cells, such as the proglucagon-derived peptides. There has been a major emphasis on two proglucagon-derived peptides, namely GLP-1 and GLP-2, due to their apparent beneficial effect on gut structure, function, and on metabolic processes. As an incretin, GLP-1 not only enhances the effect and release of insulin on pancreatic bcells but also has been implicated in having trophic effects on the intestinal epithelium. In addition, GLP-2, the other major proglucagon-derived peptide, has potent intestinotrophic effects, such as increasing the rate of mucosal stem cell proliferation, mucosal blood flow, and fluid absorption, as well as augmenting the rate of duodenal bicarbonate secretion to improve gastric mucosal health and longevity. Summary Understanding the mechanisms underlying nutrient chemosensing and how it relates to GLP release can further elucidate how the gut functions in response to cellular changes and disturbances. Furthermore, a more in-depth comprehension of GLP release and its tissue-specific effects will help improve the utility of GLP-1 and GLP-2 receptor agonists in clinical settings. This, in turn, should help patients suffering from intestinal failure, malabsorption, and mucosal injury. Keywords free fatty acid receptors, gastric mucosal defense, glucagon-like peptides, gut taste receptors, nutrient chemosensing, trophic feeds INTRODUCTION To address this point, it is important to Over the past decade, many findings and pheno- understand the interplay between trophic feeding mena have been discovered regarding luminal and nutrient chemosensing, the cellular process of nutrient absorption and the clinical intervention recognizing luminal nutrients present in the gut known as ‘trophic feeding’, used to perfuse lumen that involves specific taste receptors. Unlike nutrients, often at low rates, into the gut lumen the oral cavity, which contains five distinct classes and thus promote gut health. More recent studies of taste receptors, the intestines only express three: have suggested that the luminal nutrients contained umami (proteinaceous), sweet, and bitter, the latter in these feeds trigger a signaling cascade that containing a multitude of subclasses. Each of these releases gut hormones, which subsequently lead to the mucosal protective effects observed in the aCollege of Letters & Sciences, University of California, Los Angeles, gastrointestinal tract [1]. In this review, we aim b c to support this hypothesis through a thorough Research Service, West Los Angeles VAMC and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, summary of recent findings regarding gut hormones California, USA and their release following mucosal exposure to Correspondence to Jonathan D. Kaunitz, MD, Research Service, West luminal nutrients. These findings are important Los Angeles VAMC, 11301 Wilshire Blvd (115/217E), Los Angeles, CA not only for establishing the mechanism behind 90073, USA. Tel: +1 310 268 3879; fax: +1 310 268 4811; the success of trophic feeds but also for identifying e-mail: [email protected] which nutrients may optimally regenerate entero- Curr Opin Gastroenterol 2016, 32:461–466 cytes and reestablish overall gut health. DOI:10.1097/MOG.0000000000000316 0267-1379 Copyright ß 2016 Wolters Kluwer Health, Inc. All rights reserved. www.co-gastroenterology.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Stomach and duodenum endogenously-produced FAs may be sufficient to KEY POINTS release gut hormones, further implicating exogen- Glucagon-like peptides (GLPs) play an important role in ous SCFAs as possible therapeutic mucosal agents intestinal regeneration and growth as well as with the ultimate aim of repairing intestinal glucose metabolism. damage. Additional studies that parallel Kripke’s findings also support the concept of SCFA-induced Taste receptors (TASRs) are expressed not only in the intestinal mucosal growth. In a piglet model, SCFA- oral microflora but throughout the gastrointestinal tract and have been implicated in incretin release and induced trophic effects occurred in portions of promoting gut health. the intestine not originally exposed to the SCFA infusions, suggesting that these trophic effects did Free fatty acid receptors (FFARs) have been co- not require direct mucosal exposure [7]. Although localized to enteroendocrine cells with GLPs and help there is ample evidence to support the notion that mediate their release as a part of a wider nutrient chemosensing process. SCFAs signal mucosal protective effects, it has been previously widely accepted that the trophic effects Bile acid receptors expressed on L cells modulate TASR of SCFAs, specifically butyrate, are mainly derived and FFAR-dependent GLP release. from fueling enterocyte growth [8]. This school of thought was based on prior observations that epi- thelial cells absorb SCFAs and are damaged when receptors is a G-protein coupled receptor (GPCR) directly exposed to high concentrations SCFAs in heterodimer, comprising combinations of members vitro, before the discovery of SCFA-specific GPCRs. of taste receptor families (TAS1R and TAS2R), which The concept of trophic feeds has subsequently been result in distinct and discrete perceptions of taste widely established and implemented clinically; [2&]. Umami receptors comprise TAS1R1 and TAS1R3, luminal exposure to small amounts of SCFAs may whereas sweet taste receptors combine TAS1R2 and thus be useful in patients receiving parenteral nutri- TAS1R3 [3]. In addition to this first family (TAS1R) of tion due to their prevention of the mucosal atrophy taste receptors, there is a second type (TAS2R) that is that occurs in the absence of luminal nutrients. utilized exclusively by bitter taste receptors. There Two major similarities between TASRs and free are over 25 known human subtypes of TAS2Rs, FA receptors (FFARs) are the observation that their conferring over 300 possible GPCR heterodimers activation reverses mucosal atrophy and maintains [4]. Similar to the oral taste receptors, taste receptors appropriate glucose metabolism when activated, in the gut are responsible for maintaining energy effects that are at least partially mediated by gluca- balance and glycemic control during digestive gon-like peptides (GLPs). These biomolecules processes. To accomplish this goal, taste receptors are proteolytically cleaved from proglucagon via signal the release of a large variety of paracrine prohormone convertase 1/3, a process responsible and endocrine gut hormones that elicit functional for the production of the two peptides expressed physiological responses throughout the gastrointes- in enteroendocrine L-cells: GLP-1 and GLP-2 [8]. tinal tract [5]. Together, taste receptors coupled to GLP-1 is highly expressed in enteroendocrine L-cells hormone release help maintain metabolic processes, throughout the gastrointestinal tract, where it release gut hormones, and ultimately promote serves as an incretin that helps maintain glycemic intestinal health. control. Like GLP-1, GLP-2, also expressed in L-cells, In addition to taste receptors, there are a wide has many intestinotrophic properties, such as variety of biomolecules that elicit a physiological increasing the rate of crypt enterocyte proliferation, response through activation of nutrient chemosen- increasing the rate of mesenteric artery blood flow, sors. One such group of molecules is fatty acids and increasing crypt-villus depth [9&]. The GLP-2 (FAs), which are sensed by specific and distinct receptor (GLP-2R) is expressed in subepithelial peri- GPCRs based on the length of the respective carbon cryptal myofibroblasts and enteric neurons, which tail. Two such classes are short-chain FAs (SCFAs) further support its proposed function as major inter- and long-chain FAs (LCFAs), which are shorter mediate in many cell-signaling pathways [10,11]. than eight and longer than 16 carbons, respectively. Amongst other functions, many of these pathways An important early study conducted by Kripke’s are believed to decrease inflammation in gastroin- group in 1989 [6] suggested that exogenous SCFA testinal, hepatic, pulmonary, and muscular tissues infusion was trophic for the intestine, in particular [12&]. The proteolytic enzyme dipeptidyl peptidase by increasing the rate of mucosal cell growth and IV (DPPIV) has major specificity for GLP hormones, accelerating maturation of the villous cells. Because governing their plasma t1/2. DPPIV inhibition, by SCFAs are generated by the oral microflora in increasing the plasma t1/2 of GLP-1, is used clinically addition to the gut flora, an acute load of these in the treatment of type 2 diabetes [13,14&,15&] and 462 www.co-gastroenterology.com Volume 32 Number 6 November 2016 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Gastrointestinal defense mechanisms
Load more

Recommended publications
  • G Protein-Coupled Receptors As New Therapeutic Targets for Type 2 Diabetes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Diabetologia (2016) 59:229–233 DOI 10.1007/s00125-015-3825-z MINI-REVIEW G protein-coupled receptors as new therapeutic targets for type 2 diabetes Frank Reimann1 & Fiona M. Gribble 1 Received: 31 October 2015 /Accepted: 9 November 2015 /Published online: 12 December 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract G protein-coupled receptors (GPCRs) in the gut– GLP1R Glucagon-like peptide 1 receptor brain–pancreatic axis are key players in the postprandial con- GPBAR1 G protein-coupled bile acid receptor trol of metabolism and food intake. A number of intestinally GPCR G protein-coupled receptor located receptors have been implicated in the chemo-detection of ingested nutrients, and in the pancreatic islets and nervous system GPCRs play essential roles in the detection of many Therapeutics that promote insulin secretion have been a main- hormones and neurotransmitters. Because of the diversity, stay of type 2 diabetes treatment for many years. However, cell-specific expression and ‘druggability’ of the GPCR su- with the rising impact of obesity on the incidence of type 2 perfamily, these receptors are popular targets for therapeutic diabetes comes an increasing need to target body weight as development. This review will outline current and potential well as blood glucose control. Recent years have witnessed an future approaches to develop GPCR agonists for the treatment increasing interest in the gut endocrine system as a source of of type 2 diabetes.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Metabolite Sensing Gpcrs: Promising Therapeutic Targets for Cancer Treatment?
    cells Review Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? Jesús Cosín-Roger 1,*, Dolores Ortiz-Masia 2 , Maria Dolores Barrachina 3 and Sara Calatayud 3 1 Hospital Dr. Peset, Fundación para la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO, 46017 Valencia, Spain 2 Departament of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] 3 Departament of Pharmacology and CIBER, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] (M.D.B.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +34-963851234 Received: 30 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: G-protein-coupled receptors constitute the most diverse and largest receptor family in the human genome, with approximately 800 different members identified. Given the well-known metabolic alterations in cancer development, we will focus specifically in the 19 G-protein-coupled receptors (GPCRs), which can be selectively activated by metabolites. These metabolite sensing GPCRs control crucial processes, such as cell proliferation, differentiation, migration, and survival after their activation. In the present review, we will describe the main functions of these metabolite sensing GPCRs and shed light on the benefits of their potential use as possible pharmacological targets for cancer treatment. Keywords: G-protein-coupled receptor; metabolite sensing GPCR; cancer 1. Introduction G-protein-coupled receptors (GPCRs) are characterized by a seven-transmembrane configuration, constitute the largest and most ubiquitous family of plasma membrane receptors, and regulate virtually all known physiological processes in humans [1,2]. This family includes almost one thousand genes that were initially classified on the basis of sequence homology into six classes (A–F), where classes D and E were not found in vertebrates [3].
    [Show full text]
  • Retinal Energy Demands Control Vascular Supply of the Retina in T Development and Disease: the Role of Neuronal Lipid and Glucose Metabolism
    Progress in Retinal and Eye Research 64 (2018) 131–156 Contents lists available at ScienceDirect Progress in Retinal and Eye Research journal homepage: www.elsevier.com/locate/preteyeres Retinal energy demands control vascular supply of the retina in T development and disease: The role of neuronal lipid and glucose metabolism ∗ ∗∗ Jean-Sébastien Joyala,b, , Marin L. Gantnerc, Lois E.H. Smithd, a Department of Pediatrics, Pharmacology and Ophthalmology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, Qc, Canada b Department of Pharmacology and Therapeutics, McGill University, Montreal, Qc, Canada c The Lowy Medical Research Institute, La Jolla, United States d Department of Ophthalmology, Harvard Medical School, Boston Children's Hospital, 300 Longwood Avenue, Boston MA 02115, United States 1. Introduction The metabolic and energy needs of the retina have been assumed to be met by glucose, as the retina is part of the CNS, and the brain relies Neuronal energy demands are met by a tightly coupled and adaptive almost exclusively on glucose (Mergenthaler et al., 2013). There are vascular network that supplies nutrients and oxygen. The retina is one two primary pathways that cells can use to generate ATP from glucose, of the highest energy-consuming organs, exceeding the metabolic rate glycolysis and oxidative phosphorylation. However, Cohen and Noell of the brain; blood vessels grow and regress in reaction to changes in concluded in 1960 that a substantial portion of the energy produced these high demands (Ames et al., 1992b; Anderson and Saltzman, 1964; through oxidation by the retina (around 65%) was not derived from Yu and Cringle, 2001).
    [Show full text]
  • Activation Mechanism of the G Protein-Coupled Sweet Receptor Heterodimer with Sweeteners and Allosteric Agonists
    Supporting Information Activation mechanism of the G protein-coupled sweet receptor heterodimer with sweeteners and allosteric agonists Soo-Kyung Kim, *† Yalu Chen, † Ravinder Abrol, †, ‡ William A. Goddard III,*† and Brian Guthrie§ †Materials and Process Simulation Center (MC 139-74), California Institute of Technology, 1200 E. California Blvd., Pasadena, CA 91125; ‡Current address, Departments of Chemistry and Biochemistry, California State University, Northridge, CA 91330; §Cargill Global Food Research, 2301 Crosby Road, Wayzata, MN 55391 * CORRESPONDING AUTHOR Prof. William A. Goddard III California Institute of Technology MC 139-74, 1200 E. California Blvd., Pasadena, CA 91125; phone: 1-626-395-2731, e-mail: [email protected] Dr. Soo-Kyung Kim phone: 1-626-395-2724, e-mail: [email protected] 1 RESULTS Structures for Allosteric ligand bound at the TMD of all three TAS1Rs As described in the METHODS section, the DarwinDock procedure (1) involves sampling ~50,000 poses for each of ~10 diverse ligand conformations from which, we select finally two energetically favorable binding poses based on two scoring methods: UCav E: unified cavity energy for which we consider that interactions of the best 100 poses with the union of all residues involve in their separate binding sites (providing a uniform comparison) BE: snap binding energy considering all interactions of ligand with protein As a first validation of the predicted structures for the 7 helix TMD, we used DarwinDock to predict the binding site for the allosteric ligands to each TAS1R TMD in Table S10. Here we find, S819 [1-((1H-pyrrol-2-yl)methyl)-3-(4-isopropoxyphenyl)thiourea] is a sweet compound that interacts with the TAS1R2 TMD.(2) and Lactisole is a competitive inhibitor of the sweet taste receptor that binds to TAS1R3 TMD.(3, 4) These structures were further relaxed through annealing.
    [Show full text]
  • The Association of Bovine T1R Family of Receptors Polymorphisms with Cattle Growth Traits ⇑ C.L
    Research in Veterinary Science xxx (2012) xxx–xxx Contents lists available at SciVerse ScienceDirect Research in Veterinary Science journal homepage: www.elsevier.com/locate/rvsc The association of bovine T1R family of receptors polymorphisms with cattle growth traits ⇑ C.L. Zhang a, J. Yuan a, Q. Wang a, Y.H. Wang a, X.T. Fang a, C.Z. Lei b, D.Y. Yang c, H. Chen a, a Institute of Cellular and Molecular Biology, Xuzhou Normal University, Xuzhou, Jiangsu, PR China b College of Animal Science and Technology, Northwest Agriculture and Forestry University, Shaanxi Key Laboratory of Molecular Biology for Agriculture, Yangling, Shaanxi, PR China c College of Life Science, Dezhou University, Dezhou, Shandong 253023, PR China article info abstract Article history: The three members of the T1R class of taste-specific G protein-coupled receptors have been proven to Received 12 August 2011 function in combination with heterodimeric sweet and umami taste receptors in many mammals that Accepted 20 January 2012 affect food intake. This may in turn affect growth traits of livestock. We performed a comprehensive eval- Available online xxxx uation of single-nucleotide polymorphisms (SNPs) in the bovine TAS1R gene family, which encodes receptors for umami and sweet tastes. Complete DNA sequences of TAS1R1-, TAS1R2-, and TAS1R3-cod- Keywords: ing regions, obtained from 436 unrelated female cattle, representing three breeds (Qinchuan, Jiaxian Red, Taste receptors Luxi), revealed substantial coding and noncoding diversity. A total of nine SNPs in the TAS1R1 gene were SNP identified, among which seven SNPs were in the coding region, and two SNPs were in the introns.
    [Show full text]
  • (Rs12033832) and Sweet Taste Perception Amongst Malay Obese and Non- Obese Subjects Ahmad Riduan Bahauddin1, Nazamid Shaari2, Zalilah Mohd Shariff3, Roselina Karim2
    Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346) ORIGINAL ARTICLE Association Between TAS1R2 Gene Polymorphism (rs12033832) and Sweet Taste Perception Amongst Malay Obese and Non- obese Subjects Ahmad Riduan Bahauddin1, Nazamid Shaari2, Zalilah Mohd Shariff3, Roselina Karim2 1 Faculty of Food Science and Nutrition, Universiti Malaysia Sabah, Jln. UMS, 88400 Kota Kinabalu, Sabah, Malaysia 2 Department of Food Technology, Faculty of Food Science and Technology, Universiti Putra Malaysia, 43000, Serdang, Selangor, Malaysia 3 Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43000 Serdang, Selangor, Malaysia ABSTRACT Introduction: A growing evidence supported that variation of sweet taste perception, mediated by TAS1Rs gene variants could lead to excess sweetened food and beverages intake and also obesity. However, obesity development may also alter individuals' taste sensitivity and perception. Thus, it is best to further investigate whether or not the individuals' sweet taste sensitivity and acceptance are associated with variation in TAS1R2 gene and Body Mass Index (BMI) status. Methods: This comparison cross sectional study comprised of 88 obese and 92 non-obese subjects aged 20-45. All the subjects were genotyped for TAS1R2 gene variant at rs12033832 using polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP). Suprathreshold sensitivity for sweet taste was assessed using general Labeled Magnitude Scales. Intensity rating and hedonic test were carried out on 2 food samples (tea drink and rose flavoured agar) to examine subject's intensity rating and liking at different sugar contents. Results: Our re- sults showed that rs12033832 of TAS1R2 gene is associated with sweet taste perception among obese and non-obese subjects.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • The Potential Druggability of Chemosensory G Protein-Coupled Receptors
    International Journal of Molecular Sciences Review Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors Antonella Di Pizio * , Maik Behrens and Dietmar Krautwurst Leibniz-Institute for Food Systems Biology at the Technical University of Munich, Freising, 85354, Germany; [email protected] (M.B.); [email protected] (D.K.) * Correspondence: [email protected]; Tel.: +49-8161-71-2904; Fax: +49-8161-71-2970 Received: 13 February 2019; Accepted: 12 March 2019; Published: 20 March 2019 Abstract: G protein-coupled receptors (GPCRs) belong to the largest class of drug targets. Approximately half of the members of the human GPCR superfamily are chemosensory receptors, including odorant receptors (ORs), trace amine-associated receptors (TAARs), bitter taste receptors (TAS2Rs), sweet and umami taste receptors (TAS1Rs). Interestingly, these chemosensory GPCRs (csGPCRs) are expressed in several tissues of the body where they are supposed to play a role in biological functions other than chemosensation. Despite their abundance and physiological/pathological relevance, the druggability of csGPCRs has been suggested but not fully characterized. Here, we aim to explore the potential of targeting csGPCRs to treat diseases by reviewing the current knowledge of csGPCRs expressed throughout the body and by analysing the chemical space and the drug-likeness of flavour molecules. Keywords: smell; taste; flavour molecules; drugs; chemosensory receptors; ecnomotopic expression 1. Introduction Thirty-five percent of approved drugs act by modulating G protein-coupled receptors (GPCRs) [1,2]. GPCRs, also named 7-transmembrane (7TM) receptors, based on their canonical structure, are the largest family of membrane receptors in the human genome.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]